ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO254

Piperacillin/Tazobactam Dosing Recommendation in Critically Ill Patients Receiving Tablo Kidney Replacement Therapy

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Lewis, Susan J., University of Findlay, Findlay, Ohio, United States
  • Mueller, Bruce A., University of Michigan, Ann Arbor, Michigan, United States

Tablo kidney replacement therapy (KRT) machines provide flexibility in treatment duration, frequency, and effluent rates to treat ICU patients with AKI. These KRT options may clear piperacillin/tazobactam (PIP/TAZ) differently than conventional KRTs. This study’s purpose was to predict PIP/TAZ doses likely to attain the efficacy targets in critically ill patients receiving Tablo KRT, using Monte Carlo simulation (MCS).


Pharmacokinetic models were developed using pertinent demographic & pharmacokinetic parameters to predict PIP/TAZ exposure in 5,000 virtual, anuric patients receiving 5 different KRT regimens (Table 1). PIP/TAZ doses with 0.5 or 4 hour infusions were simulated to assess the probability of target attainment (PTA). The 3 PIP efficacy targets used were 1) free plasma concentrations above the MIC for ≥50% of the dosing interval (≥50% fT>MIC), 2) free concentrations for ≥50% of the dosing interval ≥4 times above the MIC (≥50% fT >4xMIC), or 3) 100% fT >MIC. Breakpoint MIC used was 16 mg/L for P. aeruginosa. TAZ target was ≥50% fT> threshold concentration of 4 mg/L. The toxicity risk of each PIP dose was predicted with using a safety threshold (157 mg/L). The smallest doses attaining PTA≥90% during 1-week of therapy were considered optimal.


PIP/TAZ doses attaining the different efficacy targets in the 5 KRT settings are shown in Table.


MCS predicted the same PIP/TAZ doses for 3x/wk HD, daily HD, sequential HD/UF, and PIKRT while higher doses are necessitated for extended therapy. Higher doses were required for aggressive efficacy targets, but these were likely to increase the toxicity risk. These findings need clinical validation.


  • Commercial Support – Outset Medical